Breaks Categories: News

WednesdayJun 17, 2026 10:33 am

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) Completes AI and Quantum Computing Pilot for PNKP Inhibitor Program 

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising.  Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) announced the successful completion of a pilot project with Kuano Ltd. that supports advancement of the company's PNKP Inhibitor Technology (ONC010) through AI-enabled and quantum-based computational analysis. Kuano delivered molecular modeling and computational findings that strengthened Onco's understanding of how its PNKP inhibitor and related analogs may interact with the target, producing a refined structural hypothesis for PNKP inhibition and establishing a framework for structure-based optimization and future evaluation. The project also applied quantum-based computational methods to assess PNKP structural behavior and develop human PNKP structural models for follow-on…

Continue Reading

WednesdayJun 17, 2026 9:00 am

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Advances AI-Powered GMP Manufacturing Platform

Oncotelic Therapeutics (OTCQB: OTLC) announced the completion of key Phase 2 objectives in its manufacturing automation initiative with TechForce Robotics, advancing commercialization of an AI-powered good manufacturing practices manufacturing services platform at SAPU Bio, the company's 45%-owned sterile injectable cGMP manufacturing joint venture. The Phase 2 deployment expands the capabilities of Oncotelic's proprietary PDAOAI(TM) platform across sterile manufacturing operations, electronic batch records, GMP workflow execution, cleanroom monitoring and autonomous materials movement. The company said the integrated platform combines PDAOAI(TM) with TechForce's autonomous robotic systems to support intelligent pharmaceutical manufacturing and create potential opportunities in software licensing, automation deployment, manufacturing partnerships…

Continue Reading

TuesdayJun 16, 2026 1:57 pm

BioMedNewsBreaks — Humacyte Inc. (NASDAQ: HUMA) Prices $50 Million Public Offering 

Humacyte (NASDAQ: HUMA) announced the pricing of an underwritten public offering of 47.6 million shares of common stock at $1.05 per share, with expected gross proceeds of approximately $50 million before underwriting discounts, commissions and offering expenses. The company also granted underwriters a 30-day option to purchase up to an additional 7.1 million shares at the public offering price. The offering is expected to close on or about June 12, 2026, subject to customary closing conditions. Humacyte said it intends to use the net proceeds to support commercialization of Symvess(R), advance a planned Biologics License Application supplement filing for a hemodialysis indication, fund development of pipeline candidates and provide working capital…

Continue Reading

ThursdayJun 11, 2026 3:58 pm

BioMedNewsBreaks — OptimizeRx Corp. (NASDAQ: OPRX) Secures $35 Million Senior Credit Facility 

OptimizeRx (NASDAQ: OPRX), a provider of healthcare technology solutions for life sciences companies, announced that it has entered into a $35 million senior secured credit facility with Fifth Third Bank. The facility consists of a $25 million term loan and a $10 million revolving credit facility that was undrawn at closing. Roth Capital Partners served as financial advisor on the transaction. To view the full announcement, visit https://ibn.fm/G0Fj3 About OptimizeRx OptimizeRx is a leading healthcare technology company that’s redefining how life science brands connect with patients and healthcare providers. Our platform combines innovative artificial intelligence (AI)-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant,…

Continue Reading

ThursdayJun 11, 2026 10:40 am

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Completes Business Combination and Begins Trading on Nasdaq

VERAXA Biotech (NASDAQ: VRXA) announced the successful closing of its previously announced business combination with Voyager Acquisition Corp. (NASDAQ: VACH), resulting in the formation of VERAXA Biotech AG, which will begin trading on the Nasdaq Capital Market under the ticker symbol VRXA, with warrants trading under VRXAW. The company is developing a pipeline of bispecific T-cell engagers and antibody-drug conjugates based on its proprietary BiTAC platform, which is designed to selectively target cancer cells while sparing healthy tissue. VERAXA said proceeds from recently completed financings, including a $27.5 million senior secured note and a securities purchase agreement of up to…

Continue Reading

WednesdayJun 10, 2026 9:30 am

BioMedNewsBreaks – Earth Science Tech, Inc. (OTC: ETST) Highlights Fiscal 2026 Growth and Cash Flow Progress in Shareholder Letter

Earth Science Tech (OTC: ETST) provided a business update in a letter to shareholders, highlighting what management described as a transformational fiscal year ended March 31, 2026. The company cited progress across multiple holdings, including the expansion of Mister Meds, turnarounds at DOConsultation and Villas Health, the relaunch of MyOnlineConsultation as a cash flow-positive prescriber network and revenue growth at Peaks that surpassed $2 million during the first week of the fourth quarter. Earth Science Tech said it completed these initiatives without adding debt to its balance sheet, while also repurchasing and retiring more than 3.7 million shares during the…

Continue Reading

WednesdayJun 10, 2026 9:10 am

BioMedNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) Advances ONC010 Manufacturing Process Development

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) announced the initiation of process development and intermediate scale-up activities for A83B4C63, the active pharmaceutical ingredient in its proprietary drug candidate ONC010. The work represents a key milestone in the company's chemistry, manufacturing and controls strategy as it advances toward IND-enabling studies and planning for first-in-human clinical evaluation. Onco said the program will focus on optimizing synthetic processes, improving yield and reproducibility and scaling production of key intermediates required for downstream manufacturing and formulation. The…

Continue Reading

TuesdayJun 09, 2026 9:40 am

BioMedNewsBreaks – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Delivers First Edge AI Intoxication Detection Kiosk Prototypes

This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising. MindBio’s Edge AI Kiosks Use Voice and AI to detect intoxication and fatigue. MindBio Therapeutics (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) announced the completion and delivery of its first prototype Edge AI Intoxication Detection Kiosks, a hardware and software platform designed to detect intoxication and fatigue through AI-powered voice analysis. The kiosks are intended for workplace environments and are being developed to help improve safety across industries where drug, alcohol and fatigue monitoring are critical. The company said the prototypes will now undergo testing,…

Continue Reading

MondayJun 08, 2026 1:15 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights Oversubscribed $22.5 Million Financing and Growth Strategy in Investor Presentation

CNS Pharmaceuticals (NASDAQ: CNSP) announced its participation in a virtual investor segment featuring Chief Financial Officer Steve O'Loughlin, who discussed the company's recently completed oversubscribed $22.5 million financing. The presentation focused on the factors supporting the successful capital raise following CNS Pharmaceuticals' strategic reset and acquisition-focused transformation. Management also addressed investor reception to the company's evolving strategy, the participation of healthcare-focused institutional investors and how the strengthened balance sheet positions CNS Pharmaceuticals to pursue potential transformational opportunities. The discussion highlighted the company's long-term growth strategy and efforts to create shareholder value as it advances its next phase of development. To…

Continue Reading

MondayJun 08, 2026 12:00 pm

BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Advances European Commercial Launch Plans for GelrinC

Regentis Biomaterials (NYSE American: RGNT) announced plans to begin European surgeon training activities in the third quarter of 2026 as part of preparations for the commercial rollout of GelrinC(R), its CE Mark-approved treatment for knee cartilage lesions. The hands-on program will provide orthopedic surgeons with practical experience using the company's cell-free implant and is expected to begin at Humanitas Research Hospital in Milan, Italy, with additional sessions planned across Europe. The company said the training initiative is a key step in its European commercialization strategy and will be supported by a network of Centers of Excellence focused on surgeon education, clinical guidance and knowledge sharing. GelrinC is designed as…

Continue Reading